Last updated: September 7, 2026
Voxzogo (vosoritide) has become BioMarin Pharmaceutical’s fastest-growing commercial franchise, supported by orphan-drug protection, biologic exclusivity, limited competition and expansion into younger children with achondroplasia. Revenue increased from a late-2021 launch base to roughly $760 million in 2024, but long-term growth depends on earlier diagnosis, treatment adoption, international reimbursement, daily injectable administration and the ability to extend treatment before growth plates close. The principal medium-term risk is not conventional generic entry. It is label expansion by competing growth-modifying therapies and eventual follow-on biologic competition after U.S. exclusivity periods expire.
Vosoritide Market Dynamics, Revenue Growth, Patent Protection and Competitive Outlook
What is vosoritide and what is Voxzogo used for?
Vosoritide is a recombinant modified C-type natriuretic peptide, or CNP, marketed by BioMarin as Voxzogo. It is approved for children with achondroplasia who have open growth plates. The drug increases endochondral bone growth by counteracting excessive signaling through the FGFR3 pathway, which is the central molecular defect in achondroplasia.
The treatment is administered by subcutaneous injection, generally once daily. Clinical benefit is measured primarily through annualized growth velocity and changes in height, rather than reversal of established skeletal abnormalities. Treatment therefore has the greatest commercial and clinical value before epiphyseal closure.
The U.S. Food and Drug Administration approved Voxzogo in November 2021 for children at least 5 years old with achondroplasia and open growth plates. FDA later expanded the indication to include younger children, increasing the addressable population and extending the commercial treatment window (FDA, 2023).
What patient population does vosoritide target?
Achondroplasia is the most common form of disproportionate short stature. Published estimates generally place prevalence near one case per 15,000 to 25,000 live births. The global affected population is estimated in the tens of thousands, but the commercially addressable population is smaller because treatment requires confirmed diagnosis, open growth plates, access to specialist care and reimbursement.
The market has several structural limits:
- Patients must begin treatment before growth plates close.
- Daily injection creates adherence and caregiver burden.
- Long-term treatment duration is uncertain.
- Some patients and families may decline pharmacologic height modification.
- Payers may require documentation of skeletal maturity, diagnosis and treatment response.
- Diagnosis and referral are concentrated among pediatric endocrinologists, geneticists and skeletal-dysplasia centers.
How large is the vosoritide market?
The commercial market is an orphan specialty market with high annual treatment value per patient rather than a mass-market product. BioMarin has not publicly disclosed a single global list price that applies across all markets because pricing and reimbursement differ by country.
Voxzogo’s growth has been driven by regulatory approvals in the United States, Europe and other regions, rising diagnosis rates, specialist adoption and treatment of older children who became eligible after launch.
Vosoritide revenue trajectory
The following figures summarize BioMarin’s reported or company-disclosed Voxzogo revenue trajectory. Amounts are rounded and should be read as reported product revenue, not treated-patient counts.
| Fiscal year |
Approximate Voxzogo revenue |
Commercial development |
| 2021 |
About $30 million |
U.S. launch in the fourth quarter |
| 2022 |
About $190 million |
Initial international expansion and payer access |
| 2023 |
About $530 million |
Broader uptake and expanded U.S. age eligibility |
| 2024 |
About $760 million |
Continued international growth and larger treated population |
BioMarin reported total 2024 revenue of approximately $3 billion, making Voxzogo one of the company’s largest growth products. The product moved from a launch-stage asset to a material contributor to corporate revenue within three years (BioMarin, 2025).
What is driving vosoritide revenue growth?
The main drivers are:
- Expansion of the eligible age range.
- Greater diagnosis and referral of children with achondroplasia.
- Reimbursement approvals in additional countries.
- Conversion of untreated prevalent patients.
- Longer treatment duration among children who start therapy early.
- Use in markets where specialist centers have established treatment protocols.
Revenue growth should moderate as the prevalent pool of easily identifiable untreated patients declines. Later growth will depend more heavily on incident pediatric patients, earlier initiation and geographic expansion.
When does vosoritide lose exclusivity?
Vosoritide has several overlapping exclusivity layers. No single date determines competitive entry.
| Protection |
U.S. relevance |
Expected timing |
| Orphan-drug exclusivity |
Prevents approval of the same drug for the same orphan indication, subject to statutory exceptions |
Seven years from November 2021 approval, generally through November 2028 |
| Biologic data exclusivity |
FDA cannot approve a biosimilar relying on the reference product’s data for 12 years after first licensure |
Generally through November 2033 |
| Pediatric exclusivity |
May add six months to applicable regulatory exclusivity if granted |
Product-specific and dependent on FDA completion of written pediatric studies |
| Patent protection |
Depends on issued claims, terminal disclaimers, patent-term adjustment and any later formulation or manufacturing patents |
Potentially extends beyond regulatory exclusivity |
The 12-year U.S. reference-product exclusivity period is more important than the orphan period for biosimilar timing. A biosimilar sponsor could potentially prepare and file before the exclusivity date under the U.S. biosimilar framework, but FDA approval would generally remain blocked until the applicable data-exclusivity period ends.
The exact patent expiry profile must be assessed patent by patent. Biologic exclusivity and patent protection are separate legal rights. A patent challenge can create litigation risk before data exclusivity expires, while a patent estate can delay entry after the regulatory exclusivity period ends.
What patents protect vosoritide?
Vosoritide’s protection is expected to involve several categories of intellectual property:
- Composition-of-matter claims covering modified CNP analogs.
- Sequence and structural claims directed to vosoritide or related peptides.
- Pharmaceutical-composition claims.
- Formulation and stability claims.
- Manufacturing and purification claims.
- Dosing and treatment claims for achondroplasia.
- Pediatric treatment and growth-plate-related method claims.
Because Voxzogo is a biologic, it does not use the small-molecule Orange Book framework as its principal U.S. patent-disclosure mechanism. The FDA’s Purple Book identifies licensed biological products and biosimilar relationships, but it does not provide an Orange Book-style, product-specific patent listing system.
BioMarin’s effective protection therefore depends on the interaction among issued U.S. and foreign patents, biologic exclusivity, orphan exclusivity, regulatory hurdles and the difficulty of developing a clinically and commercially acceptable follow-on product.
What formulations are protected by vosoritide patents?
Formulation protection is commercially relevant because vosoritide is a peptide administered chronically to children. Potential claim scope can include:
- Aqueous injectable formulations.
- Buffer and tonicity systems.
- Protein or peptide stabilization.
- Storage and reconstitution conditions.
- Low-dose pediatric administration.
- Pre-filled or ready-to-use delivery systems.
- Manufacturing processes that preserve peptide integrity.
Formulation patents are usually weaker than valid composition-of-matter claims because competitors may design around excipient combinations or delivery formats. They can still delay entry if the approved product depends on a narrow stability profile or if a competing formulation would require additional clinical and regulatory work.
What method-of-use patents protect vosoritide treatment?
Method-of-use patents may cover administration to children with achondroplasia, dosing schedules, treatment before growth-plate closure, and use in particular age groups. Such claims may be valuable in litigation but are often more vulnerable than composition claims because a challenger may seek a label that omits the patented use.
A narrow pediatric method patent does not necessarily block all non-infringing use of a peptide. Its commercial strength depends on whether the relevant indication can be carved out without undermining the economics of a competing product.
What is the FDA regulatory status of vosoritide?
Voxzogo is FDA-approved for improving linear growth in children with achondroplasia and open growth plates. It is not approved to eliminate the underlying FGFR3 mutation or to correct all skeletal complications associated with achondroplasia.
Important regulatory characteristics include:
- Biologic product status.
- Orphan-drug designation.
- Pediatric indication.
- Subcutaneous daily administration.
- Reliance on growth velocity and height outcomes.
- Ongoing need for long-term safety and skeletal-outcome monitoring.
Regulatory expansion into younger children has high commercial importance. Earlier treatment increases potential years of therapy and may improve lifetime height gain, but it also increases the duration of exposure and the amount of pediatric safety data required.
What is the Orange Book and Purple Book status of Voxzogo?
Voxzogo is a biologic, so an Orange Book listing should not be expected in the same form used for conventional small-molecule drugs. The relevant regulatory reference is the FDA Purple Book.
The Purple Book does not function as a complete public patent register for biologics. Investors and competitors must separately analyze BioMarin’s issued patents, patent-family continuity, regulatory exclusivity and any litigation involving follow-on products.
No FDA-approved vosoritide biosimilar has been identified in the public regulatory record through the end of 2024. No approved generic version exists.
Which companies are challenging vosoritide?
No major commercial biosimilar challenger had publicly established an approved or launched competing vosoritide product through the end of 2024. The competitive threat is developing through two channels.
Direct follow-on biologic competition
A biosimilar or interchangeable product would need to demonstrate high similarity to vosoritide and address the clinical, analytical and manufacturing complexity of a peptide biologic. Although vosoritide is smaller and structurally simpler than many antibody products, it still requires control of sequence, folding, impurities, aggregation, potency and delivery.
Potential sponsors include large generic manufacturers, biosimilar specialists and companies with pediatric endocrinology portfolios. A public Paragraph IV-style challenge is not the expected framework for a biologic. The relevant pathway is the Biologics Price Competition and Innovation Act, generally through a 351(k) application and associated patent-notice procedures.
Competing growth-modifying therapies
The more immediate strategic threat may come from products that address the same clinical goal through a different mechanism. Ascendis Pharma’s TransCon CNP is a long-acting CNP-based therapy designed to reduce dosing frequency. It has potential to compete on convenience, adherence and treatment burden if approved for achondroplasia.
A long-acting CNP product could affect Voxzogo even without identical molecular composition. Its commercial effect would depend on efficacy, safety, dosing frequency, reimbursement, launch timing and physician confidence.
How does vosoritide compare with competing therapies?
| Attribute |
Voxzogo, vosoritide |
Long-acting CNP competitors |
Growth hormone or other approaches |
| Mechanism |
Modified CNP analog that counteracts FGFR3 signaling |
CNP-pathway modulation, potentially extended exposure |
Different growth-related mechanisms |
| Administration |
Daily subcutaneous injection |
Potentially less frequent injection |
Varies |
| Regulatory status |
FDA-approved for eligible children with achondroplasia |
Development- and approval-dependent |
Indication-specific |
| Commercial advantage |
First approved pharmacologic therapy for the core growth problem |
Convenience and adherence potential |
Established infrastructure in some disorders |
| Main limitation |
Daily dosing, expense and limited treatment window |
Clinical differentiation and regulatory execution |
May not address achondroplasia biology directly |
Voxzogo benefits from first-mover status and established treatment pathways. A competitor with less frequent dosing could pressure net pricing and retention even if Voxzogo remains clinically effective.
What patent litigation affects vosoritide?
No major publicly disclosed U.S. patent litigation involving a commercial vosoritide biosimilar had materially disrupted Voxzogo sales through the end of 2024. The litigation profile is therefore different from that of high-volume small-molecule drugs with multiple Paragraph IV filings.
Future disputes could involve:
- Validity of peptide composition claims.
- Written-description and enablement requirements.
- Obviousness of modified CNP sequences.
- Patent-term calculations.
- Infringement by a follow-on peptide.
- Manufacturing and purification claims.
- Formulation and stability claims.
- Method-of-use claims for pediatric treatment.
The absence of current litigation does not establish a weak patent estate. It may reflect the early stage of the product’s life cycle and the fact that U.S. biologic data exclusivity remains in force.
What licensing deals affect vosoritide?
BioMarin is the principal commercial sponsor of vosoritide. The asset is closely associated with BioMarin’s internal rare-disease and skeletal-dysplasia strategy rather than a widely syndicated licensing structure.
No major public out-licensing transaction has become a central valuation variable for Voxzogo. Commercial partnerships and regional distribution arrangements may exist, but they have not displaced BioMarin as the key economic beneficiary.
This matters for financial analysis. Unlike products dependent on a royalty-heavy licensing chain, Voxzogo’s revenue contribution is more directly connected to BioMarin’s gross sales, commercial infrastructure and pricing strategy.
How strong is the vosoritide patent estate?
The estate is commercially strong in the near term because four barriers operate together:
- FDA biologic exclusivity through approximately 2033.
- Orphan exclusivity through approximately 2028.
- Composition, formulation and manufacturing patents.
- A specialized pediatric indication with limited near-term market scale.
Its long-term strength is harder to judge from public information without a claim-by-claim validity and freedom-to-operate analysis. Composition claims provide the strongest protection. Method-of-use and formulation claims are more susceptible to design-around strategies.
The practical entry barrier is higher than the patent estate alone suggests because a competitor would need a reliable pediatric product, specialist adoption, reimbursement and evidence supporting use in a rare disorder.
What generic entry risks exist for vosoritide?
The risk of conventional generic entry is negligible because vosoritide is a biologic peptide. The relevant threat is biosimilar or follow-on peptide entry.
Near-term risk: low
Before U.S. biologic data exclusivity expires, an approved competing product would face substantial regulatory and patent barriers. A competitor could develop manufacturing capability and file when permitted, but commercial launch would remain constrained.
Medium-term risk: moderate
After approximately 2033, a biosimilar sponsor could seek approval under the 351(k) pathway. Entry could still be delayed by valid patents, litigation, manufacturing complexity or limited market size.
Long-term risk: meaningful
Once multiple products compete, price erosion could be material. The size of the erosion will depend on interchangeability, payer policy, specialty-pharmacy control and whether patients remain on treatment for several years.
What are the main market dynamics for vosoritide?
The market has five defining characteristics.
Treatment adoption is front-loaded
Families and physicians who view increased linear growth as valuable may begin treatment soon after diagnosis. Uptake can be slower where reimbursement committees require extensive documentation or where long-term outcome data are limited.
The eligible pool turns over
Children age out of treatment as growth plates close. BioMarin must replace those patients with newly diagnosed children or expand use to younger ages. This creates a recurring commercial requirement that differs from chronic adult medicines with indefinite use.
Geography matters
The United States, major European markets, Japan and other high-income countries are the primary revenue centers because diagnosis, specialist care and reimbursement are more developed. Emerging markets may have large unmet need but lower pricing and weaker access.
Daily dosing affects persistence
A daily injection is a commercial liability relative to a long-acting alternative. Persistence may improve as caregivers become familiar with administration, but injection fatigue can reduce duration of therapy.
Pricing power is constrained by orphan economics
Voxzogo’s rare-disease positioning supports a high price per treated patient. Payers can still impose prior authorization, age restrictions, treatment-response requirements and renewal criteria. A competing product with lower administration burden could force discounts even before a biosimilar arrives.
What is the revenue exposure for BioMarin?
Voxzogo is strategically important because it is one of BioMarin’s fastest-growing products and is less exposed to immediate small-molecule generic erosion than older specialty medicines. Its revenue contribution is large enough that a slowdown would affect BioMarin’s growth profile and valuation.
The principal financial risks are:
- Slower uptake in newly eligible age groups.
- Reimbursement restrictions.
- Competition from long-acting CNP therapies.
- Safety findings affecting long-term pediatric use.
- Difficulty sustaining annual growth after prevalent patients are treated.
- Foreign-exchange pressure in international markets.
- Future biosimilar price erosion.
- Patent or regulatory outcomes that narrow the treatment window.
The principal upside drivers are earlier diagnosis, treatment initiation at younger ages, broader international reimbursement, expanded indications and evidence linking treatment to durable functional outcomes.
What are the likely vosoritide launch scenarios?
| Scenario |
Commercial outcome |
| Base case |
Continued growth through international expansion, followed by moderation as the untreated prevalent population declines |
| Upside case |
Earlier pediatric treatment, broad reimbursement and strong persistence drive revenue toward a billion-dollar-plus franchise |
| Competitive case |
A long-acting CNP competitor reduces new-patient share and pressures net price before biosimilar entry |
| Patent and exclusivity case |
Regulatory exclusivity protects the product through the early 2030s, with biosimilar risk emerging thereafter |
| Downside case |
Reimbursement limits, adherence problems or safety concerns reduce treatment duration and renewal rates |
What are the key takeaways for investors and business-development teams?
- Vosoritide is an approved first-in-class therapy for growth impairment associated with achondroplasia.
- BioMarin’s product revenue increased rapidly after the 2021 U.S. launch and reached roughly $760 million in 2024.
- U.S. orphan exclusivity is expected to run to approximately November 2028.
- U.S. biologic data exclusivity is expected to run to approximately November 2033.
- Voxzogo is not a conventional Orange Book generic opportunity.
- No approved vosoritide biosimilar or major commercial Paragraph IV-style challenger had emerged through the end of 2024.
- The main near- and medium-term competitive risk is a longer-acting CNP therapy, not a conventional generic.
- Patent strength is highest for composition claims and less certain for formulation and method-of-use claims.
- Future revenue depends on early diagnosis, younger-age treatment, reimbursement and persistence.
- BioMarin’s financial exposure is rising because Voxzogo has become a major growth product.
FAQs about vosoritide market and exclusivity
Is vosoritide a biologic or a small-molecule drug?
Vosoritide is a recombinant modified peptide biologic. Follow-on competition would generally proceed through the U.S. biosimilar framework rather than a conventional ANDA generic pathway.
Does Voxzogo have a biosimilar competitor?
No FDA-approved vosoritide biosimilar had been identified through the end of 2024. The commercial risk is likely to increase after U.S. biologic data exclusivity expires in approximately 2033.
Can vosoritide be used after growth plates close?
No. The approved treatment concept depends on open growth plates. Once epiphyseal growth is complete, the biological basis for increasing linear growth is substantially reduced.
Could a long-acting CNP product replace Voxzogo?
A long-acting CNP therapy could take share if it provides comparable or superior growth outcomes with fewer injections. Replacement would depend on regulatory approval, physician adoption, payer coverage and relative pricing.
Why is the Purple Book more relevant than the Orange Book for Voxzogo?
The Purple Book applies to licensed biological products and biosimilar relationships. The Orange Book is primarily used for approved small-molecule drugs and their listed patents and exclusivity periods.
References
-
BioMarin Pharmaceutical Inc. (2025). Annual report for the fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission.
-
Food and Drug Administration. (2021). FDA approves first drug for children with achondroplasia, a rare form of short stature. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2023). FDA expands approval of Voxzogo for children with achondroplasia. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119.
-
European Medicines Agency. (2021). Voxzogo: EPAR - product information. European Union.
